

BIOMARKERS & IMMUNO US 2024

BY OXFORD GLOBAL

Book Now



28 – 29 October 2024 | San Diego, CA

Delivering advanced, commercially validated biomarkers, diagnostics and immunotherapies to meet unmet medical need and facilitate precision medicine



7 Content Tracks



300+ Meeting Opportunities



400+ Attendees



25+ Partners

70+ Industry-Leading Speakers Including...



I-MING WANG,
Director Translational
Oncology, **Pfizer**



SUZANNE COBERLY,
Senior Director,
Bristol Myers Squibb



ARPITA RAY, Principal Scientist,
Genentech



JEAN-FRANCOIS MARTINI
Executive Director –
Diagnostics & Translational
Oncology Lead, **Pfizer**



PHILIP ARLEN, President
& Chief Executive Officer,
Precision Biologics



DAVID WEINGEIST, Scientific Director,
Oncology Precision Medicine,
**Johnson Johnson Innovative
Medicine**



RUCHI GUPTA
Head of Translational
Science, **Alector**



ROBERT GETZENBERG,
US Lead, Diagnostics,
Astellas Pharma Inc.



KRISTINA MCGUIRE, Executive
Director & Head CDx, Precision
Medicine, **Regeneron**



WELCOME TO

Biomarkers & Immuno US 2024

Committed to helping you facilitate breakthroughs in developing the latest safe and effective precision treatments, Biomarkers & Immuno US provides meaningful networking opportunities and pioneering content from across the biomarkers, diagnostics and immunotherapy industries.

Precision medicine is creating new opportunities to understand the fundamental biology of diseases, identify new molecular targets and utilize emerging technologies to support the development of innovative therapies tailored to the patients who will benefit most. The conference brings together experts developing precision immunotherapies with scientists paving the way with biomarker strategies and diagnostic tools to enable precision treatments not just for oncology but neuroscience, rare disease and more. With a

blend of engaging presentations from leading pharma and biotech companies, alongside a range of interactive sessions to drive innovation & encourage cross-industry collaboration, it'll enable you to receive the insights & connections you need to advance your company's work further across 2024 and beyond.



Eszter Sutowski Nagy

Director of Editorial & Event Content,
Oxford Global

2 High-Level Events in 1

Biomarkers & Immuno US features two co-located conferences:

- Biomarkers & Precision Medicine US Congress
- Advances in Immunotherapy US Congress

You'll benefit from specialized programmes for each topic, as well as combined networking opportunities across the entire audience. In particular, the shared programme allows for knowledge-sharing between experts working a wide variety of drug development stages and therapeutic areas to remove bottlenecks and integrate new approaches into workflows.



Unlock The Latest News & Insights

Sign up for our monthly newsletter to keep up with all things Immuno

[Click Here](#)



BROCHURE CONTENTS

[Welcome](#)

[Attendees](#)

[Sponsors](#)

[Attendees](#)

[Confirmed Speakers](#)

[Programme Highlights](#)

[Agenda: Day One](#)

[Agenda: Day Two](#)

[Venue Information](#)

[Oxford Global Plus Pass](#)

[Forthcoming Events](#)

[Book Now](#)

[LinkedIn](#)

[@OGConferences](#)



WHAT'S NEW

Benefits Of Attending

Why Attend?

- ✓ **Enable effective biomarker identification and characterization across multiple disease areas**, including neuroscience, oncology & rare disease, to accelerate novel drug candidates to commercially successful products
- ✓ **Integrate multi-omic technologies into your workflows to drive the development of precision medicines**, with discussion of spatial technologies, single cell analysis and AI-driven imaging
- ✓ **Ensure your late stage development is set up for success.** Streamline your route through the clinic with the successful implementation of effective trial design strategies, and ensure scalability of your product
- ✓ **Take a deep dive into clinical & pre-clinical development with discussions on animal modelling techniques and screening strategies** to assess safety and efficacy & Regulatory considerations for effective clinical trials
- ✓ **A high-quality programme devised with the help of our esteemed advisory board.** Our revamped programme reflects the cutting edge challenges facing the immunotherapy industry in 2024 and beyond. The 2 days will provide in-depth discussion of the key immune-targeting modalities transforming patient care – including cell & gene therapies, therapeutic antibodies, vaccines, viruses & the microbiome
- ✓ **Gain novel insights into next-generation diagnostic tools in order to improve clinical outcomes.** Further talks look at the implementation of companion diagnostics in drug development to enable therapeutic success



BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

LinkedIn

@OGConferences



WHY PARTNER WITH OXFORD GLOBAL?

At Oxford Global, our mission is to curate personalized experiences that foster community and inspire innovation.

We believe in the power of networking, connection, and knowledge to deliver quality products and services that exceed expectations. Partnering with Oxford Global means having a dedicated team committed to helping you achieve your goals and navigating the industry's ever-changing landscape.

✓ Arrange 1-2-1 Meetings

Benefit from guaranteed one-to-one face time with your key prospects, with detailed pre-meeting information provided to enable effective and productive conversations.

✓ Speaking Opportunities

Showcase your company's recent work to a relevant and highly engaged audience.

✓ Host Panel & Roundtable Discussions

Feature alongside key opinion leaders to discuss current hot topics and highlight your company's expertise.

✓ Organise Workshops

Demonstrate best practice within the industry in front of your peers with case studies from your clients.

✓ Exhibit your Products & Solutions

Promote your offerings and ensure delegates know where to find you with a prominent brand presence in the exhibition hall.

✓ Digital Marketing & Lead Generation

Accessing the Oxford Global database, amplify your thought leadership and branding messaging through a post-event case study e-Book.

[LEARN MORE](#)



DRIVE INNOVATION & ACCELERATE RESEARCH

Who Is Partnering?


Gold Sponsor



Silver Sponsor



Bronze Sponsors



Network & Programme Sponsors



BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

[Book Now](#)



@OGConferences



NETWORK & KNOWLEDGE-SHARE

Attendees

400+ VPs, Directors & Senior Managers will be attending on-site and online, coming from leading healthcare, biotech, pharma & research institutions in the following fields & more

- Immuno- Oncology
- Immunology
- Preclinical Development
- Translational Medicine
- Cell Therapy
- Antibody Engineering
- Biomarker Identification
- Immune Monitoring
- Clinical Biomarkers
- Personalized Medicine
- Companion Diagnostics
- Assay Development
- Biomarker Discovery & Validation
- Data Analysis

Formal & informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Formal 1-2-1 meetings will be available to arrange prior to the event which take place during the dedicated networking breaks covering:

- Target validation
- Animal Models
- Biomarker Identification
- Immune Monitoring
- Screening
- Assay Development
- Contract Research
- Imaging Technologies
- Liquid Biopsies

Previous Attendee Profile:

Function

Manager/Senior - 31%



Director - 28%

Scientist - 17%



C-Level - 14%

Head/Lead - 10%

Geography



Sector



Attended by these companies & many more:

sanofi

SERVIER

astellas

Genentech
A Member of the Roche Group

Pfizer

Lilly

REGENERON

MERCK

Bristol Myers Squibb™



GAIN EXPERTISE FROM THOUGHT LEADERS

Confirmed Speakers

KEY SPEAKERS



Day Two | 9:00

SATYA SAXENA
Director, Eisai



Day Two | 8:35

RUCHI GUPTA
Head of Biomarker
Development & Operations,
Alector



Day One | 14:15

JEAN-FRANCOIS MARTINI
Executive Director,
Translational Oncology Lead,
Pfizer



Day One | 09:00

PHILIP ARLEN, President
& Chief Executive Officer,
Precision Biologics



Day One | 14:40

OLIVER HE, Professor,
University Michigan



Day One | 14:15

ANTONIO F. SANTIDRIAN,
Chief Scientific Officer, Caldi
Biotherapeutics

BIOMARKERS US SPEAKERS

KYUHO HAN

Chief Executive Officer, MEDiC Life Sciences

ANURAAG SHRIVASTAV

President, Oncodrex

RUCHI GUPTA

Head of Biomarker Development & Operations, Alector

JEAN-FRANCOIS MARTINI

Executive Director, Translational Oncology Lead, Global Product Development, Oncology, Pfizer

JADWIGA BIENKOWSKA

Senior Director, Computational Biology ORD, Pfizer

KRISTINA MCGUIRE

Executive Director and Head of CDx & Lab Operations, Precision Medicine, Regeneron

MATTHIAS VON HERRATH

Vice President, Novo Nordisk

YIMING ZHU

Senior Director, Biomarker Sciences, Avidity Biosciences

JONATHAN SIMS

Senior Director, Eli Lilly

ROBERT GETZENBERG

Medical Director Diagnostics, Oncology, Astellas Pharma Inc.

DAVID WEINGEIST

Scientific Director, Oncology Precision Medicine & Diagnostics, Johnson & Johnson Innovative Medicine

SATYA SAXENA

Director, Global Proteomics, Clinical Pharmacology & Translational Medicine, Eisai

SOUMYA PODDAR

Associate Director of Translational Sciences, Kite, A Gilead Company

ANAND GIDDABASAPPA

Head of Global Science & Technology, Comparative Medicine, Pfizer

XUEMEI ZHAO

Senior Principal Scientist, MSD

SRIPAD RAM

Digital Pathology and Image Analysis Lead, Pfizer

VITALAY FOMIN,

Chief Executive Officer, Numenos

RAWAN TARAWNEH

Associate Professor, School of medicine, Department of Neurology, University of New Mexico

JOSEPH MCDERMOTT

Computational Biologist, Lantern Pharma

LOKESH AGRAWAL

Program Director, National Cancer Institute

MANOJ KANDPAL

Director of Bioinformatics Research, The Rockefeller University

IRYNA VOLOSHYNA,

Senior Research Scientist, NYU Grossman School of Medicine

ARPITA RAY

Principal Scientist, Genentech

ANSHU AGRAWAL

Professor Of The Division Of Basic & Clinical Immunology, University Of California, Irvine

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

LinkedIn

@OGConferences



GAIN EXPERTISE FROM THOUGHT LEADERS

Confirmed Speakers

IMMUNO US SPEAKERS

SUZANNE COBERLY

Senior Director, Bristol Myers Squibb

LINDA ZHANG

Senior Principal Scientific Researcher,
Genentech

GREG DEENER

Chief Executive Officer, iCell Gene
Therapeutics

I-MING WANG

Director Translational Oncology, Pfizer

SHANTHERI PAI

Associate Director, Clinical Operations
Oncology, Gilead Sciences

PHILIP ARLEN

President & Chief Executive Officer,
Precision Biologics

ANTONIO F. SANTIDRIAN

Chief Scientific Officer, Caldi
Biotherapeutics

CHAKRAVARTHY GARLAPATI

Senior Scientist, Molecular & Cellular
Pharmacology, Alkermes

OLIVER HE

Professor, University Michigan

MEHRAN MOGHADDAM

Chief Executive Officer, Orox
Biosciences

KC HART

Senior Scientist, IGM Biosciences

BROCHURE CONTENTS

Welcome

Attendees

Sponsors

Attendees

Confirmed
Speakers

Programme
Highlights

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

LinkedIn

@OGConferences

DAY ONE OVERVIEW

Monday 28 October 2024

Day one provides attendees with a wide range of presentations addressing the challenges and priorities within biomarker discovery & next-gen diagnostics, clinical strategies & biomarker applications in oncology & immunology. Additionally, day 1 examines the latest research in therapeutic anti-bodies, combination therapies and cancer vaccine development.



EXPLORE CURATED & INSIGHTFUL CONTENT

Agenda At A Glance

BIOMARKERS US CONGRESS

Track 1: Novel Biomarker Discovery, Identification & Characterization

- Strategies for the identification of novel predictive biomarkers
- Overcoming challenges in new biomarker discovery
- Case studies in biomarker identification: neuroscience, rare diseases, immunology, oncology

Track 2: Effective Clinical Biomarker Strategies

- Transforming clinical development through biomarker driven clinical trials
- The use of digital measurements and endpoints in clinical trials, including the role of digital biomarkers for decentralized trials
- Leveraging RWD for clinical research

IMMUNO US CONGRESS

Track 3: Discovery & Validation of Novel Modalities – Therapeutic Antibodies, Cell & Gene Therapy, Oncolytic Viruses & Cancer Vaccines

- Novel cell therapies for autoimmunity & immunology
- Validating novel conjugates for enhanced therapeutic potential
- Optimizing mRNA cancer vaccines to maximize effectiveness and minimize side effects

Track 4: Biomarkers & Multi-Omics For Precision Oncology & Immunology

- Utilization of spatial technologies in immunotherapy
- Novel biomarkers for prediction of immunotherapy response
- Developing effective standards and guidelines for biomarkers
- Utilizing biomarkers for clinical development and clinical trials

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Attendees

Confirmed
Speakers

Programme
Highlights

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

LinkedIn

@OGConferences

DAY TWO OVERVIEW

Tuesday 29 October 2024

Day two offers a diverse range of content focusing on the latest cell & gene research from the immunotherapy field, preclinical & clinical approaches for success, multi omic applications in precision medicine and the latest updates in biomarker data analysis strategies



EXPLORE CURATED & INSIGHTFUL CONTENT

Agenda At A Glance

BIOMARKERS US CONGRESS

Track 1: Multi-Omic Applications For Precision Medicine

- Functional and multi-omic characterization of drug activity
- Leveraging AI / ML for precision medicine
- Genomic, transcriptomics, metabolomics & proteomics: techniques & approaches
- Utilizing spatial tools for biomarker identification & personalized medicine

Track 2: Innovative Technologies, Data Analysis and Strategies For Diagnostics

- Advanced diagnostics for infectious disease, including multiplex panels for disease testing
- Leveraging novel Dx/CDx in drug development
- Diagnostic regulatory requirements
- Improving clinical outcomes through novel technologies & molecular testing
- How do we leverage multiple data sources to support biomarker data & validation
- AI-powered imaging & digital pathology

BROCHURE
CONTENTS

Welcome

Attendees

Sponsors

Attendees

Confirmed
Speakers

Programme
Highlights

Agenda:
Day One

Agenda:
Day Two

Venue
Information

Oxford
Global
Plus Pass

Forthcoming
Events

Book Now

LinkedIn
X @OGConferences

DAY ONE: 28 OCTOBER 2024

08:00 **Registration Opens & Welcome Refreshments**

Welcome

Conference Room 3

08:50 **Oxford Global's Welcome Address**

Attendees

Keynote Address: Design & Development Of Monoclonal Antibodies Against Novel Cancer Targets

09:00

- The use of cancer vaccines and other immunostimulatory for oncology treatment
- Vaccine design to treat novel cancer targets

Sponsors

PHILIP ARLEN, President & Chief Executive Officer, **Precision Biologics**

Q&A session & transition time between conference rooms

Attendees

BIOMARKERS US CONGRESS

IMMUNO US CONGRESS

CONFERENCE ROOM 1: NOVEL BIOMARKER DISCOVERY, IDENTIFICATION & CHARACTERIZATION

CONFERENCE ROOM 2: EFFECTIVE CLINICAL BIOMARKER STRATEGIES

CONFERENCE ROOM 3: DISCOVERY & VALIDATION OF NOVEL MODALITIES – THERAPEUTIC ANTIBODIES, CELL & GENE THERAPY & ONCOLYTIC VIRUSES & CANCER VACCINES

CONFERENCE ROOM 4: BIOMARKERS & MULTI-OMICS FOR PRECISION ONCOLOGY & IMMUNOLOGY

Confirmed Speakers

Track Chair
ANURAAG SHRIVASTAV, President, **Oncodrex**

Track Chair
VITALAY FOMIN, Chief Executive Officer, **Numenos**

Track Chair
SHIRYA JOSHI, Scientist, **Bristol Myers Squibb**

Track Chair
POSITION AVAILABLE

Programme Highlights

Novel Non-Invasive Imaging Biomarkers In Oncology and Immunology

A Novel Clinical Biomarker For Gastric Cancer

Cell-Based Functional Assay For Screening & Characterizing Antibodies For Cancer Immunotherapy

Translating Precision Biomarkers Into The Clinic

09:25

- Landscape of in vivo imaging technology and biomarkers has expanded drastically. In this presentation I will be discussing
- Recent advances in the field of nuclear medicine to diagnose and treat cancer patients
- FLT-PET biomarker to evaluate Palbociclib resistance in cancer therapy
- Imaging biomarkers to evaluate T cell number and function.
- Beyond T-cells – Imaging myeloid/macrophage axis

Precision approaches are being applied in almost all areas of therapeutic development. Cellular components such as tissue restricted tight junction proteins are being utilized to target therapy in patients with diseases for which there are limited options, such as gastric/GEJ cancer. Implementation of such approaches requires unique efforts focused on the testing and clinical environments

- We have developed an antibody to block the activation of a pro-tumor cytokine for cancer immunotherapy
- Here we present a cell-based functional assay that was developed to screen antibody candidates
- The assay has also been used to investigate the therapeutic mechanism of action

- A translational pathologist discusses creating novel pathology research assays & successfully transferring them into drug development FIH clinical trials
- How to develop appropriate discovery research assays & data to create biomarker plans & design clinical trials for FIH
 - Determining which biomarkers & assay formats to use to support clinical biomarker plan by combining science & pragmatism
 - Regulatory & operational considerations for using spatial assays in the clinic.
 - Case studies will illustrate the above points.

Agenda: Day One

Agenda: Day Two

ANAND GIDDABASAPPA, Head of Global Science & Technology, Comparative Medicine, **Pfizer**

ROBERT GETZENBERG, Medical Director Diagnostics, Oncology, **Astellas**

LINDA ZHANG, Senior Principal Scientific Researcher, **Genentech**

SUZANNE COBERLY, Senior Director, **Bristol Myers Squibb**

Venue Information

Q&A session & transition time between conference rooms

Development Of Ultrasensitive Digital Immunoassay To Measure PD Biomarkers In Complex In Vivo Samples Using Flow Cytometry And Nanotechnology

Tumor And Product Features Predictive Of Outcome To CAR T Cells Through Lines Of Therapy In Diffuse Large B Cell Lymphoma (DLBCL)

Application Of Biomarkers For Precision Medicine In Solid Tumours

09:50

We have developed an ultrasensitive immunoassay method for quantitative measurement of Tau protein in various biological matrices. The tau pharmacodynamic biomarker plays a key role in Alzheimer's disease preclinical research by monitoring the effects of drug therapies on tau protein levels and their impact on disease progression.

- Axi-cel intervention in earlier lines is supported by a favorable immune contexture and improved product fitness
- Efficacy and toxicity might be uncoupled through product optimization

- This talk will highlight several impactful technologies and their recent applications in cancer precision medicine
- Topics will include single cell/multi-omic analysis, spatial profiling, microbiota assessment, liquid biopsy, especially ctDNA testing, emphasizing on how these technologies help in understanding disease mechanisms, treating patients and monitoring disease progression in a patient-specific way

We are leveraging LINARDA assay technology (Liquid NanoArray Digital Assay) to detect low-abundance proteins with a linear dynamic range from fg/mL to ng/mL. In LINARDA, single protein molecules sandwiched between pairs of antibody-labeled nanoparticles are differentiated and enumerated using ultra-high-sensitive flow cytometry. It offers several advantages over other immunoassay platforms, including low sample volume, enhanced sensitivity, fewer incubation steps, faster turnaround time, and a wider dynamic range.

SOUMYA PODDAR, Associate Director of Translational Sciences, **Kite, A Gilead Company**

I-MING WANG, Director Translational Oncology, **Pfizer**

Delegate are welcome to attend co-located events

Oxford Global Plus Pass

Forthcoming Events

[Book Now](#)

DAY ONE: 28 OCTOBER 2024

CONFERENCE ROOM 1: NOVEL BIOMARKER DISCOVERY, IDENTIFICATION & CHARACTERIZATION

CONFERENCE ROOM 2: EFFECTIVE CLINICAL BIOMARKER STRATEGIES

CONFERENCE ROOM 3: DISCOVERY & VALIDATION OF NOVEL MODALITIES – THERAPEUTIC ANTIBODIES, CELL & GENE THERAPY & ONCOLYTIC VIRUSES & CANCER VACCINES

CONFERENCE ROOM 4: BIOMARKERS & MULTI-OMICS FOR PRECISION ONCOLOGY & IMMUNOLOGY

MORNING BREAK



1-2-1 Meetings x4



Poster Displays

Solution Provider Presentation

Solving The Hurdles Of Clinical Trial Inefficiencies With Precise And Reliable High Throughput Protein Assessment

- High-throughput omics technologies have transformed the biomarker discovery, with proteins representing over 95% of known drug targets. The development of platforms capable of assessing proteins with sensitivity, specificity, and high throughput has enabled the integration of proteomics into clinical trial workflows, offering valuable biological and clinical insights.
- However, as these technologies have expanded to measure more samples and analytes, trade-offs in performance have often emerged. Drawing examples from real-world clinical omics studies, this presentation will introduce the SomaScan® Assay, a high-throughput proteomics solution that has scaled uniquely, maintaining unparalleled precision while simultaneously assessing over 11,000 proteins from a small sample volume. With proven utility in clinical trials, from drug target discovery to patient stratification, this
- presentation will also discuss how the SomaScan Assay has demonstrated its ability to enhance clinical trial efficiency. Additionally, the talk will explore how combining plasma proteomics with single-cell immune profiling and spatial proteomics can generate synergistic and meaningful clinical insights across various therapeutic areas.


CLARE PATERSON, Director of Clinical Research & Development, Somalogic



Humanized Mouse Models For B Cell-Driven Autoimmune Diseases: Selection Strategies And Case Studies

Recent advances in novel therapeutics, especially biologics, have provided unique opportunities to treat B cell-driven autoimmune diseases. In this presentation, we will discuss how to select relevant humanized mouse models for pharmacological evaluation of B cell-directed drug candidates

JUN WANG, Director of Scientific Engagement, GemPharmaTec



Delegate are welcome to attend co- located events

COLE JONES, Head of Business Development & Strategic Alliances, LevitasBio



Q&A session & transition time between conference rooms

Autoantibody Biomarkers Of Immune-Related Toxicity After Checkpoint Inhibition In Melanoma

- Despite the significant benefits of immune checkpoint inhibitors, they often trigger severe immune-related adverse events resulting in treatment discontinuation
- This presentation explores autoantibody (AAb) profiling using Sengenics protein microarrays to identify biomarker signatures predictive of immune-related toxicity
- This approach uncovered AAb-targeted pathways associated with checkpoint-mediated gastrointestinal toxicity in melanoma setting
- When AAb transfer in combination with checkpoint blockade was tested in humanized FcyR mice, a significant contribution to intestinal inflammation was observed
- These findings emphasize the role of AAbs as biomarkers for treatment outcomes and hold great potential enhancing patient care in the realm of cancer immunotherapy for melanoma and other cancers

IRYNA VOLOSHYNA, Senior Research Scientist, NYU Grossman School of Medicine



From Target ID Through Clinical Studies: Leveraging Multi-Omics Data To Accelerate Drug Discovery And Development

- How next-generation mass spectrometry is enabling rapid, high throughput multi-omics biomarker discovery, measuring thousands of proteins, metabolites, and lipids in every sample, across thousands of samples at a time
- How this multi-omics data is integrated using AI/ML tools to derive actionable insights for advancing drug development – from identifying optimal drug targets to biomarkers of response
- How large-scale human data assets can be employed to rapidly discover and validate biomarkers in independent populations and accelerate translation through to clinical studies

MO JAIN, Founder & Chief Executive Officer, Sapient



Prediction Of Super Response & Drug-Free Disease Control In Guselkumab Patients Using Multivariate Baseline Serum Biomarkers: Data From GUIDE Trial

Serum Olink® proteomic analysis was performed. Our data identified a combination of baseline serum analytes and clinical features to predict which psoriasis patients who maintain disease control for ≥1 year after guselkumab withdrawal

MONICA WAI LING LEUNG, Senior. Director, Head of iDerm Translational Sciences, Johnson & Johnson



Delegate are welcome to attend co- located event

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

DAY ONE: 28 OCTOBER 2024

CONFERENCE ROOM 1: NOVEL BIOMARKER DISCOVERY, IDENTIFICATION & CHARACTERIZATION

CONFERENCE ROOM 2: EFFECTIVE CLINICAL BIOMARKER STRATEGIES

CONFERENCE ROOM 3: DISCOVERY & VALIDATION OF NOVEL MODALITIES – THERAPEUTIC ANTIBODIES, CELL & GENE THERAPY & ONCOLYTIC VIRUSES & CANCER VACCINES

CONFERENCE ROOM 4: BIOMARKERS & MULTI-OMICS FOR PRECISION ONCOLOGY & IMMUNOLOGY

Q&A session & transition time between conference rooms

An Ultra-Sensitive Human pS413 TAU Assay In Cerebrospinal Fluid

To support clinical development of a therapeutic agent for neurodegenerative disease, an ultra-sensitive pS413 Tau assay in human CSF was developed, optimized, and validated as a decision-making clinical drug target engagement marker assay

XUEMEI ZHAO, Senior Principal Scientist, **MSD**

Role Of Biospecimen Science In Understanding Clinical Biomarkers and Biobanking

LOKESH AGRAWAL, Program Director, **National Cancer Institute**

Systemic Antitumor Virotherapies: Designed To Target And Attack Every Tumor, Empowering The Immune System

- Combination therapies solid tumors
- Utilizing antibody and cell immunotherapies for cancer treatment

ANTONIO F. SANTIDRIAN, Chief Scientific Officer, **Caldi Biotherapeutics**

Intrinsic Differences In Tumor Biology Due To Post Translation Modifications & Protein-Protein Interactions Lead To Racial Disparity In Breast Cancer

The theme of the presentation is to share the role of intrinsic tumor biology more specifically post-translational modification and PPI, these aspects could be one of the leading causes to racial disparity in triple negative breast cancer patients. These aspects can help to design precision medicines which could benefit the African American patients with TNBC.

CHAKRAVARTHY GARLAPATI, Senior Scientist, Molecular & Cellular Pharmacology, **Alkermes**

LUNCH BREAK

1-2-1 Meetings x3

Poster Displays

Track Chair
NEIL PFISTER, Principal Investigator, **University of Alabama at Birmingham**

Track Chair
ANSHU AGRAWAL, Professor **University Of California, Irvine**

Track Chair
SHIRYA JOSHI, Scientist, **Bristol Myers Squibb**

Track Chair
POSITION AVAILABLE

Precise Biomarker Identification With Fully Automated Spatial Multiomics

Here we present an innovative spatial multiomics workflow for the detection of proteins and RNA targets at single-cell level. Our approach offers in-depth characterization of tissues, facilitating the discovery of critical biomarkers and therapeutic targets.

EMILY MARTERSTECK, Field Application Scientist – North America, **Lunaphore**



Biomarkers Of Human Aging And Resilience


ANTHONY MOLINA, Professor of Medicine, **University of California, San Diego**



Decoding Immune Cell Function: 3D Proteomics Through Molecular Pixelation


Immune cells rely on spatial reorganization of membrane proteins to carry out their functions. Molecular Pixelation is a novel DNA sequencing-based technique that enables high-multiplex profiling of membrane protein abundance and spatial organization in single cells, revealing new phenotypes and potential biomarkers in blood cancer cells.

HANNA VAN OOIJEN, Immunology Application Scientist, **Pixelgen Technologies**



Solution Provider Presentation

Senior Representative, **Cellecta**



Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

CONFERENCE ROOM 1: NOVEL BIOMARKER DISCOVERY, IDENTIFICATION & CHARACTERIZATION

CONFERENCE ROOM 2: EFFECTIVE CLINICAL BIOMARKER STRATEGIES

CONFERENCE ROOM 3: DISCOVERY & VALIDATION OF NOVEL MODALITIES – THERAPEUTIC ANTIBODIES, CELL & GENE THERAPY & ONCOLYTIC VIRUSES & CANCER VACCINES

CONFERENCE ROOM 4: BIOMARKERS & MULTI-OMICS FOR PRECISION ONCOLOGY & IMMUNOLOGY

Q&A session & transition time between conference rooms

Biomarker Development To Evaluate The Mechanism Of Action Of Del-Desiran In A First-In-Human Ph1/2 Study In Myotonic Dystrophy 1

Myotonic dystrophy type 1 is an autosomal dominant, progressive neuromuscular disease, resulting from CTG repeat expansion in the myotonic dystrophy protein kinase gene. Pharmacodynamic activity of del-desiran was evaluated in the phase 1/2 MARINA® study to determine target engagement and subsequent modulation of mis-splicing

YIMING ZHU, Senior Director, Biomarker Services, **Avidity Biosciences**

Q&A session & transition time between conference rooms

Synthetic Lethal Biomarkers Identified Via CRISPR Screenings Predict Drug Response And Transform Cancer Treatments into Synthetic Lethal Therapies

• Synthetic lethal cancer therapies provide enhanced selectivity and efficacy. MEDiC's MCAT™ platform, leveraging millions of cancer spheroids with diverse genetic variants, identifies synthetic lethal biomarkers (SLS™) that can convert existing cancer drugs into highly effective synthetic lethal therapies with strong market potential.

KYUHO HAN, Chief Executive Officer, **MEDiC Life Sciences**

Panel Discussion: Transforming Clinical Development Through Biomarker Driven Clinical Trials

- What makes a good biomarker, and what is the necessary weight of evidence for its integration into clinical trials?
- What are the operational challenges of integrating biomarkers into clinical trial workflows?
- How to effectively communicate biomarker-driven results between researchers and clinical teams
- Where do you see the biggest need for the development of new biomarker-driven strategies in the clinical trial landscape today?

Moderator: CLARE PATERSON, Director of Clinical Research & Development, **Somalogic**

Panellists:
JEAN-FRANCOIS MARTINI, Executive Director, Translational Oncology Lead, Global Product Development, Oncology, **Pfizer**

SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology & Translational Medicine, **Eisai**

XUEMEI ZHAO, Senior Principal Scientist, **MSD**

Developing A Cancer Vaccine Platform

- History of cancer vaccine research and development (R&D)
- Existing challenges and opportunities in cancer vaccine domain
- CanVaxKB vaccine knowledgebase and its features
- Demos of using CanVaxKB for cancer vaccine analysis and design
- Perspectives of future cancer vaccine platform development

OLIVER HE, Professor **University Of Michigan**

Q&A session & transition time between conference rooms

BCMA- CD19 Combination CAR For Complete Humoral Reset

BCMA CD19 cCAR delivers complete humoral reset with all elevated autoantibodies eliminated. Results in long-term, medication-free remission with one dose, longest follow up at >4 years. Well tolerated with no CRS>1 and no ICANS, minimal infections (Grade 1 UTI only infection reported other than Covid) in 18 patients (majority are lupus nephritis patients)

GREG DEENER, Chief Executive Officer, **iCell Gene Therapeutics**

Panel Discussion: Utilizing AI/ML Technology In Biomarker Research For Immunotherapy

Moderator: SHIRYA JOSHI, Scientist, **Bristol Myers Squibb**

Panellists:
CHAKRAVARTHY GARLAPATI, Senior Scientist, Molecular & Cellular Pharmacology, **Alkermes**

VITALAY FOMIN, Chief Executive Officer, **Y AI**

JACK CHEN, Scientific Director, **AbbVie**

AFTERNOON BREAK



1-2-1 Meetings x4



Poster Displays

Plasma Proteomics for High-Throughput Biomarker Discovery

Biognosys, a leader in proteomics solutions for drug discovery and development, has reached a significant milestone by unveiling advancements in its plasma proteomics workflows on the esteemed TrueDiscovery® platform. These advancements incorporate a pioneering plasma enrichment technique, signaling a paradigm shift in deep proteome exploration characterized by exceptional data quality, reproducibility, and efficiency. Plasma proteomics is challenging with the 22 most abundant proteins constituting more than 99% of the total protein content, limiting the detection of less abundant proteins using discovery mass spectrometry-based proteomics. To address this limitation, workflows based on protein corona formation have emerged as a strong method to dig deeper into the proteome. Plasma proteins upon exposure to particles form a layer around it, known as protein corona, leading to a reduction in dynamic range and enabling of detection of lesser abundant proteins. Here, we introduce an enrichment workflow that allows for robust, quantitative, and deep enrichment of low-abundant plasma proteins, termed the P2 Plasma Enrichment System.

VALESCA ANSCHAU, Associate Scientific Director **Biognosys**



Delegate are welcome to attend co- located event

Delegate are welcome to attend co- located event

Delegate are welcome to attend co- located event

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

DAY ONE: 28 OCTOBER 2024

BIOMARKERS US CONGRESS

IMMUNO US CONGRESS

CONFERENCE ROOM 1: NOVEL BIOMARKER DISCOVERY, IDENTIFICATION & CHARACTERIZATION

CONFERENCE ROOM 2: EFFECTIVE CLINICAL BIOMARKER STRATEGIES

CONFERENCE ROOM 3: DISCOVERY & VALIDATION OF NOVEL MODALITIES – THERAPEUTIC ANTIBODIES, CELL & GENE THERAPY & ONCOLYTIC VIRUSES & CANCER VACCINES

CONFERENCE ROOM 4: BIOMARKERS & MULTI-OMICS FOR PRECISION ONCOLOGY & IMMUNOLOGY

Q&A session & transition time between conference rooms

Immune Based Biomarkers And Therapeutics For Alzheimer's Disease

Alzheimer's disease (AD) is the leading form of age-related dementia, with early diagnosis being critical as treatment becomes challenging once the disease advances. This presentation will focus on serum-based immune biomarkers for early AD and the mechanisms by which these molecules contribute to neuronal dysfunction

ANSHU AGRAWAL, Professor of the Division of Basic and Clinical Immunology, University Of California, Irvine

Delegate are welcome to attend co-located event

Therapeutic Potential Of IgM-based Bispecific Antibodies For The Treatment Of Refractory Autoimmune Disease Patients

B cell depletion therapy with rituximab has been employed for the treatment of autoimmune disease for ~20 years. Many patients do not achieve long term disease control. The bispecific CD20xCD3 IgM antibody T cell engager, imvotamab, offers the potential to deplete B cells more effectively than conventional IgGs

KC HART, Senior Scientist, IGM Biosciences

Designing Clinical Trials For Success

- Patient-centric clinical trial design
- Implementation of successful trial design strategies
- Leveraging digital technologies, AI/ML and data science for IO
- Regulatory considerations for effective clinical trials

SHANTHERI PAI, Associate Director, Clinical Operations Oncology, Gilead Sciences

Evening Roundtable Session

Roundtable Discussion 1: What Makes A Good Companion Diagnostic

- Biomarker selection
- Analytical validity & performance
- Integration with therapeutic development

Moderator: KRISTINA MCGUIRE, Executive Director and Head of CDx & Lab Operations, Precision Medicine, Regeneron

Roundtable Discussion 3: Are Cancer Vaccines The Future Of Oncology Treatment?

- The future of strategies to target tumour specific antigens using cancer vaccines
- How can cancer vaccines be integrated into standard practice for cancer treatment?
- What is the leading vaccine delivery platform for cancer therapy and why is it successful?

Moderator: OLIVER HE, Associate Professor, University Of Michigan

Roundtable Discussion 2: Navigating Industry Collaboration Across Pharmaceutical & Academic Landscape To Drive Innovation

- How can we create meaningful partnerships between industry and academia?
- How can collaboration help shape and drive the precision medicine field?

Co-Moderator: CHAKRAVARTHY GARLAPATI, Senior Scientist, Molecular & Cellular Pharmacology, Alkermes
SHRUTHI BHARADWAJ, Head of Research & Development Insights & Analytics, Sanofi

Roundtable Discussion 4: Overcoming The Immunosuppressive Tumour Microenvironment

- Strategies to overcome immuno suppression
- Are combination therapies the way forward?
- What are the drivers of immunosuppression in the TME?

Co-Moderator: MEHRAN MOGHADDAM, Chief Executive Officer, Orox BioSciences
YUANMIN XU, Associate Director, Pfizer

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

DAY TWO: 29 OCTOBER 2024

Conference Room 1

Keynote Address: The Importance Of Biomarker Data For Neurological Indications

08:35 RUCHI GUPTA, Head of Biomarker Development & Operations, **Alector**

Q&A session & transition time between conference rooms

BIOMARKERS US CONGRESS

CONFERENCE ROOM 1: MULTI-OMICS FOR PRECISION MEDICINE

Track Chair

SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology & Translational Medicine, **Eisai**

Leveraging Ultra-Deep Proteomes To Facilitate Network-Informed Biomarker Discovery For Precision Medicine

09:00 There is a growing need for new biomarkers to detect, monitor and manage a disease. The vast dynamic range of protein abundance in biological fluids hinder the detection of low abundance biomarker candidates. Here we highlight the utility of extending proteome depths to uncover novel network-informed biomarker candidates for precision medicine.

SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology & Translational Medicine, **Eisai**

CONFERENCE ROOM 2: INNOVATIVE TECHNOLOGIES & STRATEGIES FOR DIAGNOSTICS

Track Chair

RUCHI GUPTA, Head of Biomarker Development & Operations, **Alector**

Landscape Overview: Current Priorities & Challenges Within Diagnostic Development

Global regulations are changing the diagnostic landscape for routine patient testing and having a dramatic impact on clinical trials and drug development. While the focus on quality diagnostics is important, the impact to laboratories, resources, processes and timelines has created challenges and a new future state is beginning to emerge.

KRISTINA MCGUIRE, Executive Director and Head of CDx & Lab Operations, Precision Medicine, **Regeneron**

Q&A session & transition time between conference rooms

Leveraging Machine Learning For Precision Immunotherapy

09:25 This talk highlights strategies leveraging ML/AI in development of new IO Therapies.

- Identifying mechanisms of resistance to Immune Check Point Inhibitors (ICI).
- Developing multimodal predictors of response to ICI.
- Elucidating new therapies MoA, therapeutic hypothesis and translational biomarkers
- Prioritizing indications for Ph I clinical trials.

JADWIGA BIENKOWSKA, Senior Director, Computational Biology ORD, **Pfizer**

Novel Biomarker Based Platform Technology For Screening, Predictive, Prognostic And Companion Diagnostics

- One of the early events in the mechanism of oncogenesis is the deterioration of immune protection. Perturbation of immune protection against cancer manifests in the structure and function of one or more immune cells. However, this critical mechanism has not yet been fully exploited for early cancer detection and treatment.
- We have developed a platform technology based on our discovery that the localization and expression patterns of NMT1 and NMT2 present unique molecular signatures (UMS1-8).
- My talk will provide an overview of biomarkers in oncology, followed by details of our biomarker-based screening and predictive and prognostic diagnostics.

ANURAAG SHRIVASTAV, President, **Oncodrex**

Q&A session & transition time between conference rooms

Xenium And Visium HD: Complementary Spatial Technologies Built To Tackle Biology's Biggest Challenges

Unlock biomarker discovery with Chromium Single Cell, Visium Spatial, and Xenium In Situ

09:50 JOSHUA TALBOOM, Science & Technology Advisor
10x Genomics



Delegate are welcome to attend co-located event

10:15 MORNING BREAK



1-2-1 Meetings x3



Poster Displays

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

DAY TWO: 29 OCTOBER 2024

BIOMARKERS US CONGRESS

CONFERENCE ROOM 1: MULTI-OMICS FOR PRECISION MEDICINE

CONFERENCE ROOM 2: INNOVATIVE TECHNOLOGIES & STRATEGIES FOR DIAGNOSTICS

Streamlining Assay Development For Spatial Proteomics

- Overview of CellScape™ Precise Spatial Multiplexing technology and applications
- Discover how to streamline high-plex assay development for spatial biology workflows across cancer biology, immunology, and neuroscience using a hypothesis-driven approach

11:15 SHAYE HAGLER, Project Scientist, **Canopy Biosciences**



Delegate are welcome to attend co-located event

Q&A session & transition time between conference rooms


Solution Provider Presentation

11:40 Senior Representative, **Mission Bio**



Using Epigenomics And DNA Methylation To Advance Cancer Biomarkers: Technologies And Case Studies

EKATERINA GRACHEVA, Epigenomics Application Specialist, **Hologic Diagenode**



Q&A session & transition time between conference rooms

ML-Based Prediction Of Transplant Outcomes Through Blood Genomic Signature Analysis

12:05 A blood gene expression-based machine learning classifier could address the critical need for early rejection detection, personalized risk assessment, and reduction of invasive procedures in transplant patients. We applied this approach to liver and kidney transplant cohorts, identifying a set of BGE biomarkers for non-invasive monitoring, enabling personalized treatment plans, and reducing the risks of over- or under-treatment.

MANOJ KANDPAL, Director of Research Bioinformatics, **The Rockefeller University**

A Novel Companion Diagnostic Strategy For Early-Stage Bladder Cancer

Johnson & Johnson Innovative Medicine reported a 90% complete response rate in their Phase 1 study of TAR-210, a targeted releasing system for non-muscle invasive bladder cancer. A complementary urine-based screening strategy identified additional patients to tissue and offers clinical utility beyond treatment selection.

DAVID WEINGEIST, Scientific Director, Oncology Precision Medicine & Diagnostics, **Johnson & Johnson Innovative Medicine**

LUNCH BREAK



1-2-1 Meetings x3



Poster Displays

Track Chair

13:30 NEIL PFISTER, Principal Investigator, Cancer Metabolism & Cell Fate Research Lab, AI in Precision Medicine Research Group Lead, **University of Alabama at Birmingham**

Track Chair

SRIPAD RAM, Digital Pathology & Image Analysis Lead, **Pfizer**

Panel Discussion: Innovations In Single Cell & Spatial Biology To Drive Biomarker Discovery

13:30 **Moderator:** SATYA SAXENA, Director, Global Proteomics, Clinical Pharmacology & Translational Medicine, **Eisai**

Panellists: ADRIAN BENJAMIN, Global Spatial Marketing Lead, **10X Genomics**

JONATHAN SIMS, Senior Director, **Eli Lilly**

13:55 RUCHI GUPTA, Head of Biomarker Development & Operations, **Alector**

Panel Discussion: Recent Advances In Diagnostics Development

- Unpacking recent regulatory changes

Moderator: ANURAAG SHRIVASTAV, President, **Oncodrex**

Panellists: KRISTINA MCGUIRE, Executive Director and Head of CDx & Lab Operations, Precision Medicine, **Regeneron**

DAVID WEINGEIST, Scientific Director, Oncology Precision Medicine & Diagnostics, **Johnson & Johnson Innovative Medicine**

Welcome

Attendees

Sponsors

Attendees

Confirmed Speakers

Programme Highlights

Agenda: Day One

Agenda: Day Two

Venue Information

Oxford Global Plus Pass

Forthcoming Events

Book Now

DAY TWO: 29 OCTOBER 2024

BIOMARKERS US CONGRESS

CONFERENCE ROOM 1: MULTI-OMICS FOR PRECISION MEDICINE

CONFERENCE ROOM 2: INNOVATIVE TECHNOLOGIES & STRATEGIES FOR DIAGNOSTICS

Q&A session & transition time between conference rooms

An AI System To Turn Genomic & Clinical Trial Data Into Precision Medicine

- Problem: Current data, internal and external is not providing a solution for the high rate of failure in clinical trial development
- Reason: We are incapable of matching/predicting which patient would respond best to either experiment or standard of care. Therefore, leading to high failure rates of trials, and not necessarily the drug
- Solution: Developing an ability to predict how a patient would respond to drugs (experimental and standard of care) without ever taking one. Also this ability can help discovery biomarkers that could be used to identify and recruit patients that respond to the experiment drug better than standard of care

VITALAY FOMIN, Chief Executive Officer, **Numenos**

Biomarker Scoring In The Digital Pathology Era

In this presentation two examples of biomarker scoring will be presented that use novel AI and ML based strategies to develop, test and validate digital algorithms for use in clinical trials.

SRIPAD RAM, Digital Pathology & Image Analysis Lead, **Pfizer**

Q&A session & transition time between conference rooms

Identification And Usage of Machine Learning Derived Biomarkers With Lantern Pharma's RADR Platform

Demonstration of machine learning to identify molecular markers for patient selection and drug positioning. Model training and feature extraction to identify causally involved molecular features and independent biomarkers will be shown with clinical data from treatment naive tumor samples, liquid biopsy, and molecular models.

JOSEPH MCDERMOTT, Computational Biologist, **Lantern Pharma**

Panel Discussion: Moving From Correlation To Causality

Moderator: MANOJ KANDPAL, Director of Research Bioinformatics, **The Rockefeller University**

Panellists:
MATTHIAS VON HERRATH, Vice President, **Novo Nordisk**

JADWIGA BIENKOWSKA, Senior Director, Computational Biology ORD, **Pfizer**

VITALAY FOMIN, Chief Executive Officer, **Numenos**

COLE JONES, Head of Business Development & Strategic Alliances **LevistasBio**

Q&A session & transition time between conference rooms

CSF Proteomics In Preclinical Alzheimer Disease: Brain Endothelium In The Front And Center

In-depth CSF profiling, using advanced proteomics, has identified unique endothelial biomarker signatures which have strong potential as therapeutic targets in preclinical Alzheimer disease. These findings offer important insights into endothelial contributions to neurodegeneration and cognitive impairment and will pave the way towards novel biomarker and drug target discovery in AD.

RAWAN TARAWNEH, Associate Professor, School of Medicine, Department of Neurology, **University of New Mexico**

End Of Day Two

14:20

14:45

15:10

15:35




BE PART OF SOMETHING EXCEPTIONAL

Venue Information

Hilton Hotel San Diego - Mission Valley

DoubleTree by Hilton Hotel San Diego - Mission Valley



7450 Hazard Center Dr, San Diego, CA 92108


Our rooms at the DoubleTree by Hilton Hotel San Diego - Mission Valley are now sold out. However, you can still reserve directly with the hotel or explore nearby alternative options by clicking [here](#):

Directions

By Air – San Diego International Airport – The DoubleTree by Hilton San Diego – Mission Valley is 7 miles from the International Airport. A single taxi ride to the hotel will cost approx. \$40 and will take around 20 minutes. Transportation to/from the hotel is provided by Super Shuttle, Cloud 9, or other shuttle services for approx. \$10-\$15 per person. Please visit [here](#) for more information on travelling to the hotel from the airport.


By Trolley – The closest Trolley stop to the hotel is Hazard Center Station – this stop is served by the Sycuan Green Line. The hotel is a 7 mins walk from the station. When alighting at this stop, walk north on Hazard Center East Driveway towards Hazard Center Drive. Then turn left and the hotel will be on your right.

By Car – There is self-parking available (garage parking) at the hotel for \$34 (this may be subject to state local taxes). There is no valet parking at this venue. For further information please contact the hotel directly. For driving instructions and a map, please click [here](#)


Please [click here to visit the venue's website](#) & to receive more information on Hilton San Diego Mission Valley 

Book Now


Register as an Industry Delegate

If you represent a pharma or biotech research organization primarily focused on therapeutic pipeline development, click here to secure your pass. 

Register as an Academic Delegate

If you represent an academic institution and are involved in research and development, click here to request a pass. 

Register as a Vendor Delegate

If you represent solution, technology, or service providers, commercial entities, consultants, or venture capitalists with a stake in the relevant landscapes, click here to secure your attendance 



FORTHCOMING EVENTS

IMMUNO SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.



Immuno 2024

25 - 26 April 2024 | London, UK

Microbiome Drug Development: Online Symposium

24 September 2024 | BST (UTC+1)

Biomarkers & Immuno US 2024

28 - 29 October 2024 | San Diego, USA



Biologics Series

Proteins & Antibodies | Peptides | Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Biomarkers Series

Biomarkers | Biomarker & Precision Medicine
Precision Oncology

Cell & Gene Series

Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series

Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series

Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Omics Series

Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/
to explore our diverse portfolio of events
across 2024.

OXFORD
GLOBAL

PLUS

12-MONTH CONTENT AND COMMUNITY ACCESS

Oxford Global PLUS Pass

Oxford Global PLUS Pass includes
unrestricted access to all events
shown above and much more

Register Now

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com

BIOMARKERS SERIES ACROSS 2024

Join leaders, experts and researchers, connecting global pharma, biotech and academia for high-level discussions on the latest innovations.



Biomarkers Europe 2024

30 September - 01 October 2024
Basel, Switzerland

Biomarkers & Immuno US 2024

28 - 29 October 2024
San Diego, USA

Multi-Omics in Biomarker Discovery & Precision Medicine: Online Symposium

12 November 2024 | GMT (UTC+0)

Biomarkers 2025

February 2025
London, UK



Biologics Series

Proteins & Antibodies | Peptides | Oligonucleotides
Sustainability in Biologics | ADC Discovery & Development
Vaccines | Oligonucleotides Chemistry & Therapeutics

Cell & Gene Series

Gene Therapy Development
Cell Culture Advanced Therapy Development
Cell & Gene Therapy Manufacturing

Discovery Series

Organ Modelling | 3D Cell Culture
Drug Discovery Summit & Discovery Chemistry
Neuroscience Drug Development
SmartLabs Automation & Robotics

Formulation & Delivery Series

Formulation & Drug Delivery
Inhalation & Respiratory Drug Delivery
RNA Therapeutics & Delivery

Immuno Series

Advances in Immuno-Oncology
Innate Killer Cells | Oncolytic Virotherapies | Targets &
Cell Types in Immuno-Oncology

Omics Series


Next Generation Sequencing
Single Cell & Spatial Analysis | Synthetic Biology
Next Generation Sequencing & Clinical Diagnostics
Digital PCR & Liquid Biopsies |
Synthetic Biology in Discovery & Therapeutics
Spatial Biology

Visit www.oxfordglobal.com/calendar/
to explore our diverse portfolio of events
across 2024.

OXFORD
GLOBAL
PLUS

12-MONTH CONTENT AND COMMUNITY ACCESS Oxford Global PLUS Pass

Oxford Global PLUS Pass includes
unrestricted access to all events
shown above and much more

Register Now 

To receive bespoke proposal for group packages
contact us at pluspass@oxfordglobal.com